Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Hemodynamic Determinants of Activity Measured by Accelerometer in Patients With Stable Heart Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prognostic Value of Peak Oxygen Uptake in Patients Supported With Left Ventricular Assist Devices (PRO-VAD)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Mineralocorticoid receptor antagonist improves cardiac structure in Type 2 Diabetes: Data from the MIRAD Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Jonathan W Cunningham
  • Muthiah Vaduganathan
  • Brian L Claggett
  • Jenine E John
  • Akshay S Desai
  • Eldrin F Lewis
  • Michael R Zile
  • Peter Carson
  • Pardeep S Jhund
  • Lars Kober
  • Bertram Pitt
  • Sanjiv J Shah
  • Karl Swedberg
  • Inder S Anand
  • Salim Yusuf
  • John J V McMurray
  • Marc A Pfeffer
  • Scott D Solomon
Vis graf over relationer

OBJECTIVES: The authors investigated the relationship between past or incident myocardial infarction (MI) and cardiovascular (CV) events in heart failure with preserved ejection fraction (HFpEF).

BACKGROUND: MI and HFpEF share some common risk factors. The prognostic significance of MI in patients with HFpEF is uncertain.

METHODS: The authors pooled data from 3 trials-CHARM Preserved (Candesartan Cilexietil in Heart Failure Assessment of Reduction in Mortality and Morbidity), I-Preserve (Irbesartan in Heart Failure With Preserved Systolic Function), and the Americas region of TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) (N = 8,916)-and examined whether MI before or following enrollment independently predicted CV death and heart failure (HF) hospitalization.

RESULTS: At baseline, 2,668 patients (30%) had history of MI. Prior MI was independently associated with greater risk of CV death (4.7 vs. 3.5 events/100 patient-years [py], adjusted hazard ratio [HR]: 1.42 [95% confidence interval (CI): 1.23 to 1.64]; p < 0.001). Excess sudden death drove this difference (1.9 vs. 1.2 events/100 py, adjusted HR: 1.55 [95% CI: 1.23 to 1.97]; p < 0.001). There was no difference in HF hospitalization (5.9 vs. 5.5 events/100 py, adjusted HR: 1.05, 95% CI: 0.92 to 1.19) or HF death by prior MI. During follow-up, MI occurred in 336 patients (3.8%). Risk of CV death increased 31-fold in the first 30 days after first post-enrollment MI, and remained 58% higher beyond 1 year after MI. Risk of first or recurrent HF hospitalization increased 2.4-fold after MI.

CONCLUSIONS: Prior MI in HFpEF is associated with greater CV and sudden death but similar risk of HF outcomes. Patients with HFpEF who experience MI are at high risk of subsequent CV death and HF hospitalization. These data highlight the importance of primary and secondary prevention of MI in patients with HFpEF. (Candesartan Cilexietil in Heart Failure Assessment of Reduction in Mortality and Morbidity [CHARM Preserved]; NCT00634712; Irbesartan in Heart Failure With Preserved Systolic Function [I-Preserve]; NCT00095238; and Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist [TOPCAT]; NCT00094302).

OriginalsprogEngelsk
TidsskriftJACC. Heart failure
Vol/bind8
Udgave nummer8
Sider (fra-til)618-626
Antal sider9
ISSN2213-1779
DOI
StatusUdgivet - aug. 2020

Bibliografisk note

Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

ID: 62248458